Stifel Upgrades Puma Biotechnology (PBYI) to Buy After Neratinib NDA Accepted
- Futures point to higher open as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Credit Suisse More than Doubles Price Target on Puma Biotechnology (PBYI) to $111
September 22, 2016 6:36 AM EDTCredit Suisse analyst Kennen MacKay reiterated an Outperform rating and sharply raised his price target on Puma Biotechnology (NYSE: PBYI) to $111.00 (from $54.00) on increased Neratinib expectations.
MacKay commented, "We increase our PBYI TP to $111 (+$57) on increased sales expectations for neratinib in the... More
NDA Acceptance Removes Overhang on Puma Biotechnology (PBYI) - RBC
September 20, 2016 9:47 AM EDTRBC Capital analyst Simos Simeonidis weighed in on Puma Biotechnology (NYSE: PBYI) after Neratinib's NDA was accepted by FDA.
"Although this incremental positive was mostly expected, this does remove another overhang/bear argument from PBYI," Simeonidis. He continues to expect mid-2017... More
Puma Biotech (PBYI) Announces U.S. FDA Acceptance of NDA for PB272
September 20, 2016 8:12 AM EDTPuma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy.
The FDA acceptance of our NDA is an important regulatory milestone, said Alan H. Auerbach, Chief Executive Officer and President of Puma. Although the use of trastuzumab in the adjuvant setting has led to a reduction... More